GLP-1 Agonists: Dual Benefits for Diabetes and Cancer
Dr. Mohammed Shahait's team reviewed evidence that diabetes drugs called GLP-1 receptor agonists may curb prostate cancer cell growth, noting that support so far comes mainly from preclinical studies.